Skip to main content
. 2023 Jun 16;13:1105474. doi: 10.3389/fonc.2023.1105474

Figure 1.

Figure 1

Kaplan–Meier estimates of overall survival for total patients (A), progression-free survival for total patients (B), and progression-free survival for patients who received across lines therapy of pyrotinib (C). mPFS, median progression-free survival; mOS, median overall survival.